Route Map for the Discovery and Pre-clinical Development of New Drugs and Treatments for Cutaneous Leishmaniasis

Overview

Journal Int J Parasitol Drugs Drug Resist

Publisher Elsevier

Specialty Parasitology

Date 2019 Jul 20

PMID 31320296

Citations 38

Authors

Diana Caridha

Brian Vesely

Katrien Van Bocxlaer

Byron Arana

Charles E Mowbray

Sima Rafati

Silvia Uliana

Rosa Reguera

Mara Kreishman-Deitrick

Richard Sciotti

Pierre Buffet

Simon L Croft

Affiliations

Soon will be listed here.

Abstract

Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R & D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles.

Citing Articles

Bioactive Compounds with Leishmanicidal Potential from and .

Napoles Rodriguez R, Arreguez M, Corlatti A, Bach H, Catalan C, Laurella L Molecules. 2025; 30(5).

PMID: 40076264 PMC: 11901713. DOI: 10.3390/molecules30051039.

A Novel Sesterterpenoid, Petrosaspongin and γ-Lactone Sesterterpenoids with Leishmanicidal Activity from Okinawan Marine Invertebrates.

Jomori T, Higa N, Hokama S, Tyas T, Matsuura N, Ueda Y Mar Drugs. 2025; 23(1).

PMID: 39852518 PMC: 11766837. DOI: 10.3390/md23010016.

Analysis of clinical cure outcome, macrophages number, cytokines levels and expression of annexin-A1 in the cutaneous infection in patients with Leishmania braziliensis.

Silva J, Silva H, Sarmento A, Hueb M, Damazo A Rev Soc Bras Med Trop. 2024; 57:e00412.

PMID: 39082522 PMC: 11290842. DOI: 10.1590/0037-8682-0036-2024.

Combination of the Topical Photodynamic Therapy of Chloroaluminum Phthalocyanine Liposomes with Fexinidazole Oral Self-Emulsifying System as a New Strategy for Cutaneous Leishmaniasis Treatment.

Silva R, Damasio D, Coelho L, Morais-Teixeira E, Queiroz-Junior C, Souza P Pharmaceutics. 2024; 16(4).

PMID: 38675171 PMC: 11054953. DOI: 10.3390/pharmaceutics16040509.

Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development.

Castro M, Erber A, Arana B, Cota G, Denkinger C, Harrison N PLoS Negl Trop Dis. 2024; 18(2):e0011975.

PMID: 38381805 PMC: 10965092. DOI: 10.1371/journal.pntd.0011975.

References

Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D . A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol. 2000; 165(2):969-77. DOI: 10.4049/jimmunol.165.2.969. View

Schuster S, Hartley M, Tacchini-Cottier F, Ronet C . A scoring method to standardize lesion monitoring following intra-dermal infection of Leishmania parasites in the murine ear. Front Cell Infect Microbiol. 2014; 4:67. PMC: 4035563. DOI: 10.3389/fcimb.2014.00067. View

Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti R . Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist. 2019; 11:129-138. PMC: 6904836. DOI: 10.1016/j.ijpddr.2019.02.002. View

Calvo-Alvarez E, Guerrero N, Alvarez-Velilla R, Prada C, Requena J, Punzon C . Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis. PLoS Negl Trop Dis. 2012; 6(11):e1927. PMC: 3510153. DOI: 10.1371/journal.pntd.0001927. View

Lecoeur H, Buffet P, Morizot G, Goyard S, Guigon G, Milon G . Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model. PLoS Negl Trop Dis. 2007; 1(2):e34. PMC: 2100369. DOI: 10.1371/journal.pntd.0000034. View

Naik , Kalia , Guy . Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technol Today. 2000; 3(9):318-326. DOI: 10.1016/s1461-5347(00)00295-9. View

Croft S . Design of treatments for cutaneous and visceral leishmaniasis. Nihon Yakurigaku Zasshi. 2017; 149(5):220-224. DOI: 10.1254/fpj.149.220. View

Zulfiqar B, Shelper T, Avery V . Leishmaniasis drug discovery: recent progress and challenges in assay development. Drug Discov Today. 2017; 22(10):1516-1531. DOI: 10.1016/j.drudis.2017.06.004. View

Aronson N . Addressing a clinical challenge: guidelines for the diagnosis and treatment of leishmaniasis. BMC Med. 2017; 15(1):76. PMC: 5383994. DOI: 10.1186/s12916-017-0843-3. View

10.

Rocha M, Correa C, Melo M, Beverley S, Martins-Filho O, Madureira A . An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein. Diagn Microbiol Infect Dis. 2013; 75(3):282-91. PMC: 3733281. DOI: 10.1016/j.diagmicrobio.2012.11.018. View

11.

Adams E, Gomez M, Scheske L, Rios R, Marquez R, Cossio A . Sensitive diagnosis of cutaneous leishmaniasis by lesion swab sampling coupled to qPCR. Parasitology. 2014; 141(14):1891-7. PMC: 4654403. DOI: 10.1017/S0031182014001280. View

12.

Freidag B, Mendez S, Cheever A, Kenney R, Flynn B, Sacks D . Immunological and pathological evaluation of rhesus macaques infected with Leishmania major. Exp Parasitol. 2003; 103(3-4):160-8. DOI: 10.1016/s0014-4894(03)00099-7. View

13.

Grogl M, Hickman M, Ellis W, Hudson T, Lazo J, Sharlow E . Drug discovery algorithm for cutaneous leishmaniasis. Am J Trop Med Hyg. 2013; 88(2):216-21. PMC: 3583307. DOI: 10.4269/ajtmh.11-0812. View

14.

Dube A, Gupta R, Singh N . Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol. 2009; 25(9):432-9. DOI: 10.1016/j.pt.2009.06.006. View

15.

Unger A, ONeal S, Machado P, Guimaraes L, Morgan D, Schriefer A . Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg. 2009; 80(4):574-9. PMC: 3557504. View

16.

Gonzalez U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A . Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis. 2010; 51(4):409-19. DOI: 10.1086/655134. View

17.

Solomon M, Pavlotzky F, Barzilai A, Schwartz E . Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol. 2012; 68(2):284-9. DOI: 10.1016/j.jaad.2012.06.014. View

18.

Leifer C, Verthelyi D, Klinman D . Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother. 2003; 26(4):313-9. DOI: 10.1097/00002371-200307000-00003. View

19.

van den Kerkhof M, Mabille D, Chatelain E, Mowbray C, Braillard S, Hendrickx S . In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. Int J Parasitol Drugs Drug Resist. 2018; 8(1):81-86. PMC: 6114106. DOI: 10.1016/j.ijpddr.2018.01.006. View

20.

Bennis I, De Brouwere V, Belrhiti Z, Sahibi H, Boelaert M . Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review. BMC Public Health. 2018; 18(1):358. PMC: 5855994. DOI: 10.1186/s12889-018-5260-9. View